Abbvie Inc. Common Stock (ABBV) 61.50 $ABBV
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.02 (-0.19), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), GSK: 44.91 (+0.16)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 196.00 (-1.40), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), NVS: 91.76 (-0.27)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 196.00 (-1.40), AZN: 72.88 (+0.03), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40)
One Factor Driving AbbVie (ABBV) Stock Down Today
at The Street - Fri Nov 07, 10:50AM CST
Shares of AbbVie (ABBV) are down after the company was downgraded to 'market perform' to 'outperform' at BMO Capital Markets earlier on Friday.
ABBV: 61.50 (-1.21)
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 196.00 (-1.40), SRDX: 20.44 (-0.56), ABAX: 51.63 (-2.21), ABBV: 61.50 (-1.21)
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.20 (-0.81), ESRX: 77.87 (-0.05), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), ENTA: 43.33 (-0.17)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 198.58 (-1.37), PFE: 29.92 (-0.12), MRK: 59.34 (+0.08), AZN: 72.88 (+0.03), TEVA: 57.70 (-1.02), ITCI: 15.26 (-0.21), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), OMER: 17.37 (+0.09)
Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 196.00 (-1.40), ABAX: 51.63 (-2.21), ABBV: 61.50 (-1.21), HSP: 56.32 (-0.32)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 43.37 (-0.32), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)
Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 196.00 (-1.40), BIIB: 320.75 (-2.72), PRGO: 155.77 (+3.28), ABBV: 61.50 (-1.21)
Top 2 MedTech Stocks, Poised to Gain on Earnings this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:36AM CST
Medical device is one of such sectors which are projected to be highly affected by the midterm election results.
DSCI: 9.06 (+0.06), MDT: 68.10 (-0.64), UNIS: 3.58 (+0.09), COV: 92.08 (-0.52), SHPG: 198.58 (-1.37), ABBV: 61.50 (-1.21), WAG: 66.92 (+0.27)
Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 196.00 (-1.40), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), ABBV: 61.50 (-1.21)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 106.45 (-0.49), PFE: 29.92 (-0.12), LH: 100.52 (-2.41), ABBV: 61.50 (-1.21), CVD: 100.52 (-0.58)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), ACT: 245.91 (-4.47), SHPG: 198.58 (-1.37), ABBV: 61.50 (-1.21)
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries
PR Newswire - Thu Nov 06, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
TEVA: 57.70 (-1.02), LLY: 66.60 (-0.36), ABBV: 61.50 (-1.21), GSK: 44.91 (+0.16), BMY: 58.32 (-0.14)
Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 70.61 (-0.99), TEVA: 57.70 (-1.02), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNTA: 10.98 (+0.10), NVS: 91.76 (-0.27)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 112.77 (+7.82), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), SHPG: 198.58 (-1.37), DNDN: 0.94 (+0.11), SNSS: 1.63 (-0.05), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), XOMA: 3.81 (-0.31)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.93 (-1.36), GERN: 2.33 (-0.07), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
ABBVIE (ABBV) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty
Business Wire - Wed Nov 05, 7:03AM CST
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities fraud and breach of fiduciary duty claims against AbbVie, Inc. (NYSE: ABBV) ("AbbVie" or the "Company"
.
ABBV: 61.50 (-1.21)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.02 (-0.19), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), GSK: 44.91 (+0.16)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 196.00 (-1.40), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), NVS: 91.76 (-0.27)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 196.00 (-1.40), AZN: 72.88 (+0.03), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40)
One Factor Driving AbbVie (ABBV) Stock Down Today
at The Street - Fri Nov 07, 10:50AM CST
Shares of AbbVie (ABBV) are down after the company was downgraded to 'market perform' to 'outperform' at BMO Capital Markets earlier on Friday.
ABBV: 61.50 (-1.21)
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 196.00 (-1.40), SRDX: 20.44 (-0.56), ABAX: 51.63 (-2.21), ABBV: 61.50 (-1.21)
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.20 (-0.81), ESRX: 77.87 (-0.05), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), ENTA: 43.33 (-0.17)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 198.58 (-1.37), PFE: 29.92 (-0.12), MRK: 59.34 (+0.08), AZN: 72.88 (+0.03), TEVA: 57.70 (-1.02), ITCI: 15.26 (-0.21), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), OMER: 17.37 (+0.09)
Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 196.00 (-1.40), ABAX: 51.63 (-2.21), ABBV: 61.50 (-1.21), HSP: 56.32 (-0.32)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 43.37 (-0.32), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)
Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 196.00 (-1.40), BIIB: 320.75 (-2.72), PRGO: 155.77 (+3.28), ABBV: 61.50 (-1.21)
Top 2 MedTech Stocks, Poised to Gain on Earnings this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:36AM CST
Medical device is one of such sectors which are projected to be highly affected by the midterm election results.
DSCI: 9.06 (+0.06), MDT: 68.10 (-0.64), UNIS: 3.58 (+0.09), COV: 92.08 (-0.52), SHPG: 198.58 (-1.37), ABBV: 61.50 (-1.21), WAG: 66.92 (+0.27)
Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 196.00 (-1.40), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), ABBV: 61.50 (-1.21)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 106.45 (-0.49), PFE: 29.92 (-0.12), LH: 100.52 (-2.41), ABBV: 61.50 (-1.21), CVD: 100.52 (-0.58)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 196.00 (-1.40), VRX: 126.11 (-2.66), ACT: 245.91 (-4.47), SHPG: 198.58 (-1.37), ABBV: 61.50 (-1.21)
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries
PR Newswire - Thu Nov 06, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
TEVA: 57.70 (-1.02), LLY: 66.60 (-0.36), ABBV: 61.50 (-1.21), GSK: 44.91 (+0.16), BMY: 58.32 (-0.14)
Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 70.61 (-0.99), TEVA: 57.70 (-1.02), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNTA: 10.98 (+0.10), NVS: 91.76 (-0.27)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 112.77 (+7.82), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), SHPG: 198.58 (-1.37), DNDN: 0.94 (+0.11), SNSS: 1.63 (-0.05), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), XOMA: 3.81 (-0.31)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.93 (-1.36), GERN: 2.33 (-0.07), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
ABBVIE (ABBV) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty
Business Wire - Wed Nov 05, 7:03AM CST
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities fraud and breach of fiduciary duty claims against AbbVie, Inc. (NYSE: ABBV) ("AbbVie" or the "Company"
. ABBV: 61.50 (-1.21)
